Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4582 - A meta-analysis on epidemiology of ROS1 rearrangement in Asian and non-Asian population

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Pathology/Molecular Biology;  Non-Small Cell Lung Cancer

Presenters

Veena Gupta

Authors

V. Gupta1, N. Godre1, M. Alam2

Author affiliations

  • 1 Medical & Research Division, Pfizer Limited, 400051 - Mumbai/IN
  • 2 Oncology, Pfizer Limited, 2114 - West Ryde/AU
More

Resources

Abstract 4582

Background

ROS1 is now recognised as a definite molecular target in NSCLC.1 Studies showed that ROS1 positive patients are significantly younger & more likely to be non-smokers.2 Previous studies found epidermal growth factor receptor (EGFR) mutation in NSCLC was significantly higher in Asian population compared to non-Asian.3 Objective of the study is to evaluate difference between epidemiological parameters of ROS1 rearrangements in Asian & non-Asian patients by performing meta-analysis.

Methods

We systematically searched databases like PubMed & e-journals since 2011. Statistical analysis for this study was done on 20 studies (11,665 patients) conducted globally & open source software R (version 3.3.2) was used for meta-analysis.

Results

Global prevalence of ROS1 rearrangement was 2% (95% CI: 0.016- 0.026) & it was higher in Asian [2.2% (95% CI: 0.016- 0.029)] than non-Asian [1.9% (95% CI: 0.012- 0.027)] (p=0.92). Mean age of Asian & non-Asian was 54.5 yrs & 59 yrs respectively. The prevalence rate in non-Asian females, was significantly higher [3.8% (95% CI: 0.011-0.078)] than non-Asian males [0.7% (0.003- 0.012)] (p=0.003). Similarly, prevalence rate in Asian females [2.8% (95% CI: 0.019-0.038)] was higher than Asian males [2.1% (95% CI: 0.012-0.033)] (p=0.88).

Smokers in Asia were more likely to have ROS1 rearrangement [1.8% (95% CI: 0.005-0.037)] compared to non-smokers [0.6% (95% CI: 0.0004-0.0152)] (p=0.93). Whereas, prevalence rate amongst non-smokers in non-Asia [7.1% (95% CI: 0.039-0.110)] was significantly higher than smokers [0.7% (95% CI: 0.002-0.007)] (p=0.008). Clinical stage IV was more common in both population than other stages. In 5 out of 20 studies, ROS1 positivity was higher (3-12.5%) in enriched (EGFR-ve/ALK-ve) population [non-smokers 6.5% (95% CI: 0.046-0.083)] compared to overall population.

Conclusions

Our meta-analysis showed that ROS1 gene rearrangement was more prevalent in NSCLC, females, non-smokers & patients with clinical stage IV while there is no significant difference in Asians vs non-Asians.

References

1] Bubendorf et al. Virchows Arch. 2016; 469:489–503. 2] Bergethon et al. JCO. 2012; 30(8): 863-870. 3] Expert Opin Pharmacother. 2015 Jun;16(8):1167-76.

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.